Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
 
Followed By 10
Posts 2,618
Boards Moderated 0
Alias Born 06/09/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/18/2014 4:10:03 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/11/2014 4:16:07 PM
ARIAD Announces Long-Term Safety & Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical... "Business Wire" - 12/9/2014 7:35:00 AM
ARIAD Announces Follow-up Data from Phase 1 & PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leu... "Business Wire" - 12/9/2014 7:35:00 AM
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial "Business Wire" - 12/8/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/25/2014 4:22:50 PM
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia "Business Wire" - 11/24/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/21/2014 4:19:07 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/13/2014 4:28:15 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/7/2014 4:52:28 PM
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting "Business Wire" - 11/6/2014 9:44:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/5/2014 7:41:08 AM
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress "Business Wire" - 11/5/2014 7:35:00 AM
ARIAD to Present at the Stifel 2014 Healthcare Conference "Business Wire" - 11/4/2014 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 4:06:48 PM
ARIAD annuncia l'adozione di un'opinione finale per Iclusig da parte del Comitato europeo per i medicinali per uso umano "Business Wire" - 10/24/2014 10:55:00 AM
ARIAD annonce l'adoption de l'avis définitif sur l’Iclusig par le Comité des médicaments à usage humain en Europe "Business Wire" - 10/24/2014 8:48:00 AM
ARIAD meldet Bestätigung der positiven abschließenden Stellungnahme zu Iclusig durch den Ausschuss für Humanarzneimittel i... "Business Wire" - 10/24/2014 8:23:00 AM
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe "Business Wire" - 10/24/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/17/2014 4:23:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/16/2014 4:26:18 PM
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results "Business Wire" - 10/15/2014 7:35:00 AM
ARIAD rende nota la raccomandazione per Iclusig da parte del Comitato di valutazione dei rischi per la farmacovigilanza dell'... "Business Wire" - 10/10/2014 3:43:00 PM
Ariad annonce les recommandations du comité pour l’évaluation des risques en matière de pharmacovigilance de l’Agence ... "Business Wire" - 10/10/2014 10:12:00 AM
ARIAD erhält befürwortende Stellungnahme für Iclusig vom Beratenden Ausschuss für Risikobewertung im Bereich der Pharmako... "Business Wire" - 10/10/2014 7:49:00 AM
iandy   Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 57539 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical trials.gov identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.

SUMMARY

It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist